[1] NJPyV was first reported in 2014 after it was isolated from epithelial cells of a pancreatic transplant patient presenting with blindness, vasculitis, myopathy, and dermatosis.

After doctors were unable to identify known viral causes of the patient's symptoms, a research team led by virologist Ian Lipkin screened samples of affected tissue for the presence of novel viruses, and identified the genome of a novel polyomavirus.

[1] The ALTO protein is an unusual alternative splicing product of the "late region" of the genome, which canonically encodes the small and large tumor antigens; expression of ALTO has also been reported in trichodysplasia spinulosa polyomavirus.

[4] The prevalence of NJPyV is unknown, though other human polyomaviruses are fairly common and usually asymptomatic.

[5] Only a small number of studies have yet attempted to screen for NJPyV seroprevalence in the general population.